Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg.

ABSTRACT:

Purpose

Imatinib is indicated for treatment of CML, GIST, etc. The population pharmacokinetics (popPK) of imatinib in patients under long-term treatment are reported in literature. Data obtained from bioequivalence trials for healthy subjects were used to evaluate the influence of demographic and pharmacogenetic factors on imatinib pharmacokinetics (PK) in a collective without concurrent drugs, organ dysfunction, inflammation etc. In addition, the differences in PK between the healthy subjects and a patient cohort was examined to identify possible disease effects.

Methods

26 volunteers were administered orally with single dose of 400 mg imatinib. 16-19 plasma samples per volunteer were collected from 0.5 up to 72 h post-dose. The popPK was built and post hoc estimates were c

SUBMITTER: Chien YH 

PROVIDER: S-EPMC9360108 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature